Encysive’s Thelin "Approvable" For PAH: FDA Requests Additional Clinicals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An FDA "approvable" letter for Encysive’s pulmonary arterial hypertension drug Thelin (sitaxsentan) requests "additional clinical trial work," according to the firm.